Catalyst Funds Management
FLNA icon

Catalyst Funds Management’s Filana Therapeutics FLNA Stock Holding History

Catalyst Funds Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Sell
10,822
-7,278
-40% -$10.4K ﹤0.01% 641
2026
Q1 		$30.6K Buy
+18,100
New +$37.3K 0.01% 562
2025
Q4 		– Sell
-44,500
Closed -$129K – 540
2025
Q3 		$129K Buy
44,500
+25,700
+137% +$59.1K 0.02% 449
2025
Q2 		$34K Buy
+18,800
New +$33.5K 0.01% 398
2024
Q2 		– Sell
-300
Closed -$6.09K – 1547
2024
Q1 		$6.09K Buy
+300
New +$6.91K ﹤0.01% 957

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GMT Capital
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Catalyst Funds Management's FLNA Position: Q2 2026 in Review

Catalyst Funds Management reduced its Filana Therapeutics (FLNA) stake by 40% in Q2 2026, selling an estimated $10.4K and leaving 10,822 shares worth $12.9K. The position accounts for ﹤0.01% of the portfolio, ranked #641.

Catalyst Funds Management first reported a position in FLNA in Q1 2024 and has held it in 5 quarters since. The position peaked at $129K in Q3 2025. 85 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Catalyst Funds Management held 10,822 shares of Filana Therapeutics worth $12.9K as of Q2 2026.
  • Catalyst Funds Management sold 7,278 Filana Therapeutics shares in Q2 2026, an estimated $10.4K.
  • Filana Therapeutics made up ﹤0.01% of Catalyst Funds Management's portfolio in Q2 2026, its #641 holding.
  • Catalyst Funds Management first reported a position in Filana Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Catalyst Funds Management's Filana Therapeutics position peaked at $129K in Q3 2025.
  • 85 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.